Table 2.
Modalities of revascularization, medications after coronary angiography (CAG), and adverse cardiovascular events based on tertiles of serum galectin-1 levels.
| Galectin-1 Tertiles | p | |||
|---|---|---|---|---|
| <16.1 ng/mL | 16.1–22.7 ng/mL | >22.7 ng/mL | ||
| (n = 278) | (n = 278) | (n = 278) | ||
| Types of revascularization | ||||
| Percutaneous coronary intervention (PCI) | 108 (38.8) | 138 (49.6) | 157 (56.5) | < 0.001 |
| Number of stents | 2.0 (1.0–3.0) | 2.0 (1.0–3.0) | 2.0 (1.0–4.0) | 0.001 |
| Coronary artery bypass grafting (CABG) | 10 (3.6) | 7 (2.5) | 18 (6.5) | 0.055 |
| Number of grafts | 3.0 (3.0–3.0) | 3.0 (3.0–4.0) | 3.0 (3.0–4.0) | 0.155 |
| Medications after CAG, n (%) | ||||
| Aspirin | 179 (64.4) | 192 (69.1) | 216 (77.7) | 0.002 |
| Clopidogrel | 118 (42.4) | 144 (51.8) | 169 (60.8) | < 0.001 |
| ACEi/ARB | 77 (27.7) | 102 (36.7) | 132 (47.5) | < 0.001 |
| Beta-blocker | 59 (21.2) | 75 (27.0) | 92 (33.1) | 0.007 |
| Statin | 120 (43.2) | 140 (50.4) | 137 (49.3) | 0.187 |
| Adverse cardiovascular events, n (%) | ||||
| Target vessel revascularization | 17 (6.1) | 13 (4.7) | 43 (15.5) | < 0.001 |
| Nonfatal MI | 1 (0.4) | 1 (0.4) | 7 (2.5) | 0.018 |
| Nonfatal stroke | 0 (0.0) | 1 (0.4) | 2 (0.7) | 0.367 |
| Death | 4 (1.4) | 1 (0.4) | 13 (4.7) | 0.001 |
| Overall MACE | 22 (7.9) | 16 (5.8) | 65 (23.4) | < 0.001 |
Values are number (%). ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; MI, myocardial infarction; MACE, major adverse cardiovascular event.